Apr 8, 2013
By:
Adeline Siew, PhD
Teva and Lonza have announced that their joint venture will continue to develop, manufacture and market affordable, efficacious and safe biosimilars.
|
|
Experts describe best practices for sterility assurance in parenteral drug manufacturing. This article contains bonus online-exclusive material.
Apr 2, 2013
By:
Adeline Siew, PhD
Experts describe best practices for sterility assurance in parenteral drug manufacturing. This article contains bonus online-exclusive material.
|
Mar 27, 2013
By:
Adeline Siew, PhD
Shire has announced plans to acquire dry eye specialist SARcode Bioscience with the aim of expanding its ophthalmics portfolio. Under the terms of the agreement, Shire will pay $160 million upfront and SARcode shareholders will receive additional undisclosed payments upon achievement of certain clinical, regulatory and/or commercial milestones.
|
Mar 20, 2013
By:
Adeline Siew, PhD
Xceleron and JCL Bioassay have entered into a partnership that will offer drug developers access to a range of sensitive and robust analytical platforms for early clinical development across Asia, Europe, and North America.
|
Mar 19, 2013
By:
Adeline Siew, PhD
ThromboGenics' eye drug, Jetrea (ocriplasmin) has been approved in the EU for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.
|
Mar 6, 2013
By:
Adeline Siew, PhD
Roche and BioLamina have entered into a research and development agreement to jointly develop new cell culture systems for various applications, including stem cell research. The collaboration will assess laminin-based in-vitro cell culture matrices that can offer physiological microenvironments for living cells.
|
Mar 6, 2013
By:
Adeline Siew, PhD
Ilaris (canakinumab), a selective, fully human, monoclonal antibody that inhibits interleukin-1 beta (IL-1 beta), has been approved in the EU for symptomatic pain relief in patients suffering from gouty arthritis whose condition cannot be managed with current treatments.
|
Mar 6, 2013
By:
Adeline Siew, PhD
AstraZeneca's three patents protecting Crestor (rosuvastatin) have been ruled invalid by the Federal Court of Australia.
|
|
Engineering nanoparticles with optimal properties for use in cancer therapies.
Mar 2, 2013
By:
Adeline Siew, PhD
Engineering nanoparticles with optimal properties for use in cancer therapies.
|
|
